Clinical trial
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
NCT00207077 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00207077 |
|---|---|
| Title | Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors |
| Official title | A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Cetuximab + Erlotinib |
| Enrollment | 33 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Oct 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: